Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 569-572

  Bellesoeur, Audrey ^a   Carton, Edith ^a   Mir, Olivier ^a,b   Groussin, Lionel ^a   Blanchet, Benoit ^a   Billemont, Bertrand ^a   Clerc, Jérôme ^a   Goldwasser, François ^a  

^a Department of Medical Oncology Cochin Teaching Hospital Université Paris Descartes ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antitumor activity; Drug monitoring; Pharmacokinetics; Sorafenib; Thyroid cancer

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SORAFENIB; THYROGLOBULIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

AGED; ALOPECIA; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IODINE RESISTANT THYROID FOLLICULAR CARCINOMA; KIDNEY BIOPSY; LUNG EMBOLISM; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; NEPHROTIC SYNDROME; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; LUNG NEOPLASMS; PATHOLOGY; SECONDARY; THYROID NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 84904695019     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0052-7     Document Type: Article

References (15)

1. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
2. Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
3. Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437 (Pubitemid 46698720)
4. Semrad TJ, Gandara DR, Lara PN Jr (2011) Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol 3:95-100
5. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F (2012) Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Investig New Drugs 30:2046-2049
6. Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, Cabanes L, Franck N, Blanchet B, Goldwasser F (2012) Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 17:1204-1212
7. Escudier B, Szczylik C, Hutson TE, Demkow T, StaehlerM, Rolland F et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289
8. Amato R, Zhai J, Willis J, Saxena S, DeFoe M (2012) A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 10:153-158
9. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972 (Pubitemid 46202316)
10. Schneider TC, AbdulrahmanRM, Corssmit EP, MorreauH, Smit JW, Kapiteijn E (2012) Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 167:643-650
11. GnothMJ, Sandmann S, Engel K, RadtkeM(2010) In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 38:1341-1346
12. Lagas JS, vanWaterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2010) Breast cancer resistance protein and Pglycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 9:319-326
13. Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A (2013) A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist 18:379-380
14. Burger H, van TolH, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reducedintracellular drug accumulation by induction of the ABCG2(BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747-752 (Pubitemid 41351174)
15. Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386 (Pubitemid 40379262)